Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Company Overview

Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex. The company has evaluated CT1812 in clinical studies for Alzheimer’s disease and is also investigating its potential in other conditions involving neurodegeneration, including dementia with Lewy bodies.

The company was founded in 2007 and is headquartered in Purchase, New York. Its activities are primarily focused on pharmaceutical research and clinical development, with studies conducted in collaboration with research institutions and clinical sites. Cognition Therapeutics is led by President and Chief Executive Officer Lisa Ricciardi.

Key Stats

• Today's Range: $0.69 to $0.77
• 50-Day Range: $0.69 to $1.06
• 52-Week Range: $0.55 to $1.83
• Volume: 321,545 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.33
• Consensus Rating: Moderate Buy

Cognition Therapeutics Stock Analysis - MarketRank™

Cognition Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 260th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cognition Therapeutics has a consensus price target of $3.33, representing about 339.1% upside from its current price of $0.76.

Amount of Analyst Coverage

Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.22) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.33% of the float of Cognition Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cognition Therapeutics has a short interest ratio ("days to cover") of 9.94.

Change versus previous month

Short interest in Cognition Therapeutics has recently decreased by 7.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cognition Therapeutics does not currently pay a dividend.

Dividend Growth

Cognition Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.95

News Sentiment

Cognition Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cognition Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for CGTX on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CGTX
• CIK: 1455365
• Web: www.cogrx.com
• Phone: 412-481-2210
• Fax: N/A
• Employees: 14
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Cognition Therapeutics: $3.33
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +339.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 84,529,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A